Open AccessHistone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer
Author(s) -
Ramchandra V. Amnekar,
Shafqat Ali Khan,
Mudasir Rashid,
Bharat Khade,
Rahul Thorat,
Poonam Gera,
Shailesh V. Shrikhande,
Duane T. Smoot,
Hassan Ashktorab,
Sanjay Gupta
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i6.598
Subject(s) - histone deacetylase , histone deacetylase inhibitor , pharmacology , medicine , cancer , histone , cancer research , dna , chemistry , biology , genetics
The prognosis of gastric cancer continues to remain poor, and epigenetic drugs like histone deacetylase inhibitors (HDACi) have been envisaged as potential therapeutic agents. Nevertheless, clinical trials are facing issues with toxicity and efficacy against solid tumors, which may be partly due to the lack of patient stratification for effective treatments.